2025
The impact of food and drug administration-based eligibility criteria on demographic representation in current phase III clinical trials for newly diagnosed breast cancer.
Varma T, Merz L, Wang Y, Cronin A, Freedman R, Abel G, Hantel A. The impact of food and drug administration-based eligibility criteria on demographic representation in current phase III clinical trials for newly diagnosed breast cancer. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23021.Peer-Reviewed Original ResearchFood and Drug Administration criteriaFood and Drug AdministrationFood and Drug Administration guidanceEligibility criteriaNH whitesNH BlackClinical trialsSafety dataNewly diagnosed breast cancerPhase III clinical trialsMedian differencePhase III trialsUS Food and Drug AdministrationCurative-intent therapyProportion of patientsIII clinical trialsNon-Hispanic (NH)Electronic health record databaseRestrictive eligibility criteriaIII trialsCreatinine clearancePrimary endpointMedian ageSecondary endpointsInvestigational agents
2022
Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery
Garcia-Nebreda M, Zorrilla-Vaca A, Ripollés-Melchor J, Abad-Motos A, Alvaro Cifuentes E, Abad-Gurumeta A, Mena G, Grant M, Paseiro-Crespo G. Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery. Langenbeck's Archives Of Surgery 2022, 407: 2293-2300. PMID: 35441358, DOI: 10.1007/s00423-022-02515-7.Peer-Reviewed Original ResearchConceptsGastric cancer surgeryCancer surgeryERAS pathwayAdjuvant therapySurgery pathwayOncologic therapyGastric adenocarcinomaEnhanced recoveryPostoperative oncologic outcomesPre-ERAS periodERAS groupHospital stayOncologic outcomesPrimary outcomeShorter LOSResultsSeventy patientsEarly returnSurgeryIntervention studiesTherapyPatientsMedian differenceAdenocarcinomaOutcomesPathway
2020
Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug And Alcohol Dependence 2020, 211: 107968. PMID: 32268248, PMCID: PMC7529685, DOI: 10.1016/j.drugalcdep.2020.107968.Peer-Reviewed Original ResearchOpioid treatment programsMethadone accessOpioid use disorderCross-sectional studyOpioid overdose deathsCensus tractsDrive timeRural census tractsMethadone treatmentOverdose deathsUse disordersLong drive timesMethadoneTreatment programChain pharmaciesTractMedian differenceRural censusHigh ratePharmacyMedianUnited StatesPopulation
2018
The Effect of Adding Subarachnoid Epinephrine to Hyperbaric Bupivacaine and Morphine for Repeat Cesarean Delivery
Katz D, Hamburger J, Gutman D, Wang R, Lin H, Marotta M, Zahn J, Beilin Y. The Effect of Adding Subarachnoid Epinephrine to Hyperbaric Bupivacaine and Morphine for Repeat Cesarean Delivery. Anesthesia & Analgesia 2018, 127: 171-178. PMID: 29077615, DOI: 10.1213/ane.0000000000002542.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesia, ObstetricalAnalgesics, OpioidAnesthesia, ObstetricalAnesthesia, SpinalAnesthetics, LocalBupivacaineCesarean Section, RepeatDouble-Blind MethodEpinephrineFemaleHumansLabor PainMorphineMotor ActivityNerve BlockNew York CityPain MeasurementPain ThresholdPain, PostoperativePregnancyProspective StudiesRecovery of FunctionSubarachnoid SpaceTime FactorsTreatment OutcomeConceptsCesarean deliveryHyperbaric bupivacaineHD groupSpinal anesthesiaNE groupRepeat cesarean deliveryMedian differencePreservative-free morphineSixty-five patientsIncidence of hypotensionModified Bromage scaleBlock onset timeDuration of actionVital sign changesRandomized Controlled TrialsUterine closurePostoperative regressionDouble-blindEpidural catheterPain scoresProlonged surgeryDermatome levelPinprick sensationSensory blockadeBromage scale
2015
Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement
Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. European Radiology 2015, 26: 103-113. PMID: 25994198, PMCID: PMC4654989, DOI: 10.1007/s00330-015-3812-2.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationHCC patientsIpsilateral placementTumor enhancementHepatocellular carcinoma patientsROI placementContrast-enhanced MR imagingRadiologic-pathologic analysisArterial chemoembolizationCarcinoma patientsPathological correlationIntra-class correlationPatientsMR imagingClinical methodsMedian differencePathologyInterest placementHistopathology
1985
Effects of fractionated irradiation of endocrine aspects of testicular function.
Shapiro E, Kinsella T, Makuch R, Fraass B, Glatstein E, Rosenberg S, Sherins R. Effects of fractionated irradiation of endocrine aspects of testicular function. Journal Of Clinical Oncology 1985, 3: 1232-9. PMID: 3928830, DOI: 10.1200/jco.1985.3.9.1232.Peer-Reviewed Original ResearchConceptsDose-dependent increaseGerm cell depletionCell depletionTesticular functionBaseline levelsFollicle-stimulating hormone valuesTotal testosterone valuesSerum FSH levelsMedian differenceLeydig cell dysfunctionSoft tissue sarcomasSerum follicle-stimulating hormone (FSH) valuesLeydig cell functionHigh-dose radiationLH changesTubule injuryFSH levelsOnly patientsSerum FSHLH concentrationsTesticular doseHormonal alterationsHormone valuesTumor bedRadiation injury
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply